Misum Biotechnology LLC., Logo
Phone Icon (844) 602-5600

Taking Biotechnology to New Levels

Misum Biotechnology LLC., serving worldwide, offers extensive immunotherapy services. We are proud to offer unique research assistance and service towards fighting cancer and infection diseases. We provide the following services including:

• CAR Vector Design
• Transduction
• CAR T/NK Cell Activation & Expansion
• CAR Efficacy Prediction
• CAR Expression Verification
• CAR Immunophenotyping

Chimeric Antigen Receptor (CAR) Construct Design (Free For the First Time)

Recent clinical trials testing cancer immunotherapies have shown promising results for treating various cancers and infectious diseases. One such therapy involves engineering T or NK cells to express chimeric antigen receptors (CAR), which combine tumor antigen specificity with immune cell activation in a single receptor. The adoptive transfer of these CAR T or NK cells into patients has shown remarkable success in treating a variety of cancers.

We offer the free design for your CAR vector construct, including retro viral & lenti viral vectors.

Dropping Formula to Test Tube

Transduction of White Blood Cells

In vitro generation of human T and NK cells expressing CAR is important to enhance the functions of CAR-T and CAR-NK cells.

We provide the transduction service to researchers and scientists.

CAR T and NK Cell Activation/Expansion & Immunophenotyping

To ensure that CAR-immune cells retain similar phenotypic and functional characteristics as non-transduced immune cells, the CAR-engineered immune cells are typically measured for cytokine secretion, proliferation, and killing activity. However, these analyses are time-consuming, costly, and labor-intensive.

We provide this CAR engineered immune cell expansion and immunophenotyping service for researchers, scientists, and physicians.

CAR T and NK Cell Efficacy Prediction

It is very challenging to predict the efficacy of CAR-engineered immune cells.

We provide researchers the service to predict the efficacy of CAR-engineered immune cells using a high-throughput, cost-effective, and easy-to-use analysis approach.